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Introduction

Biomanufactured Pichia-based products in the market

• Pichia pastoris (Komagataella phaffii), microbial cell factory
for recombinant protein production (RPP) and metabolites
• As yeast combines:
• Cheap and fast processes
• Eukaryotic folding capacity and ability to perform
post-translational modifications
• Capacity to grow up to high cell density in mineral media
• Wide toolbox of genetic tools including Crispr
• Strong promoters with different regulations that allows
to reach high production yields
• Low hyperglycosilation native patterns
• Strains with Humanized glycosylation
• Secretion of native proteins at low levels
• Target proteins secreted to the broth with high purity

• Widely used RPP platform, over 5000 recombinant proteins successfully expressed
• Numerous products in the market, usually produced in fed-batch

FDA/EMA approved biopharmaceuticals

Other relevant industrial sectors

Enzyme-based products

Cell culture: Trypsin and growth factors
Organic acids: Building blocks for biopolymers
Biopolymers: Collagen
Cosmetics: Spider silk protein
Industrial enzymes: Lipases
Feed: Phytases

Nanobodies-based products (single-domain antibodies)

FDA approved animal-free food products
- Meat
- Milk
- Eggs

Size reduction
90%

Second preferred option for
recombinant microbial expression
Full human mAbs
150 kDa

Llama Full mAbs
80 kDa

Llama VHH
15 kda

Suitable for
microbial
expression

• Reported secreted titers up
to 25 g/L
• Reported secreted protein
purity in the supernatant
up to 98%

Recombinant
Leghemoglobin

Pichia pastoris

Continuous technology in Pichia bioprocesses
1. Powerful tool for systems biology

2. Industrial implementation of continuous biomanufacturing

- Non-Dynamic systems, steady state conditions
- Highly reliable and robust cultivations
- Suitable to study the effect of a single parameter (pH, T, growth rate,)

Advantages of continuous for biomanufacturing:

Systems biology requires high quality representative samples
-

Homogeneous cell population
Constant cell metabolic state

✓ Increased efficiency (productivity and economy)

✓ Time and cost reduction for new drugs development

✓ Space saving, lower capital and maintenance costs

✓ Enhanced bioprocess robustness and product quality

✓ Environmental impact reduction

and safety

-

FDA encourages the transition towards continuous processes to improve the bioprocess
robustness and product quality

-

The reduced cost of goods offered by the continuous processes is essential to assure the
economic viability of products not targeted to the pharma industry

Strong tool for strain and bioprocess development
-

Rational Strain Design
Rational Bioprocess Development

Pichia-based products

Advantages of P. pastoris towards continuous process implementation
- High strain stability: Expression cassettes integrated in P. pastoris genome increases strain
stability, avoiding eventual loses of episomal plasmids
- Low contamination risk: Specially with methanol-based processes
- Long experience of the Pichia community with different continuous strategies:
- Chemostat (Nutirient limited below 𝛍max)
- Turbidostat (Non nutrient limited)
- Retentostat (Nutirient limited below 𝛍max )
- Capacity to scale-up Pichia-based bioprocesses up to 100 m3
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